Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
Probing the mechanism of reduced in vivo potency of insulin detemir	105
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	52
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	52
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas	45
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	44
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance	36
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	34
Hormones, microbes, and PrEP drugs in the female genital tract	27
Guidance for interactions between antiseizure medications	26
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	26
Comorbidities and the right dose: antipsychotics	25
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	24
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury	24
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	23
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	22
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	20
Bioactivity descriptors for in vivo toxicity prediction: now and the future	19
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	18
Correction	18
A comprehensive review of the efficacy and safety of ertugliflozin	17
Pharmacokinetic evaluation of concizumab for the treatment of hemophilia	17
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	16
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	15
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	15
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	15

Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	15
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	15
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	15
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	15
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	15
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	14
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia	14
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	14
Development and hepatotoxicity of rifamycin derivatives	14
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	13
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	13
Drug-drug interactions between psychotropic medications and oral contraceptives	13
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	12
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	12
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	12
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction	12
The impact of advanced age on anticoagulant therapy for acute venous thromboembolism	12
Population pharmacokinetic–pharmacodynamic analysis of givinostat	12
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity	12
Risk factors and prediction for DILI in clinical practice	12
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	12
PBPK models of the female reproductive tract: current and future analysis	11
Practical perspectives on addressing hepatotoxicity during clinical candidate selection	11
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	11
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation	11
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	11
Interactions between phytotherapeutics and chemotherapeutics: the current evidence	11
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes	10
Understanding pharmacokinetic variability in women across different life stages	10
Positioning the new drugs for migraine	10
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome	10
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study	10
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction	10
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies	10
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants	10
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects	10
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	10
Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug–drug interactions	10
Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far	9
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention	9
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults	9
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers	9
Pharmacokinetics of apixaban in patients with short bowel syndrome: a Bayesian re-estimation approach	9
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	9
Lessons learned from aldehyde dehydrogenases as non-P450 aldehyde-oxidizing enzymes: implications for the ‘exposome’ and human health	9
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications	8
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	8
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	8
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	8
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	8

Overcoming barriers to machine learning applications in toxicity prediction	8
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	8
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	8
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	8
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	8
Drug interactions in people with HIV treated with antivirals for other viral illnesses	8
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease	8
Managing intoxications with nicotine-containing e-liquids	8
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	8
Interindividual variability in statin pharmacokinetics and effects of drug transporters	7
Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review	7
Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment	7
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	7
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	7
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?	7
Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens	7
DILI prediction in drug development: present and future	7
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol	7
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	7
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	7
Drug–drug interactions in HIV-infected patients receiving chemotherapy	7
A comparative study on the consistency of different decision support software systems from the perspective of potential drug–drug interactions in intensive care unit patients	7
Drug–drug interactions involving antipsychotics and antihypertensives	7
A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens	7
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	7
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers	7
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	7
Psychedelics, psychiatry and pharmacokinetics - where are we now?	7
Optimizing drug therapy during pregnancy: a spotlight on population pharmacokinetic modeling	7
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation	7
Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes	6
A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database	6
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment	6
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia	6
The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis	6
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy	6
Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma	6
In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity	6
Benzodiazepines and clozapine co-prescription in clinical practice: a systematic review and expert recommendations	6
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs	6
Paternal exposure to antiseizure medications and offspring outcomes: a systematic review and meta-analysis of observational studies	6
How can we better address the pharmacokinetics of antipsychotics in children and adolescents?	6
Screening tools to evaluate the neurotoxic potential of botanicals: building a strategy to assess safety	6
Lessons learned from the influence of CYP2C9 genotype on warfarin dosing	6
Cephalosporins with warfarin increase the risk of bleeding: myth or fact?	6
Genetic variation in organic cation transporters and considerations in drug development	6
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer	6
The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review	5
Individualizing doses of antiepileptic drugs	5
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	5
Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniques	5
The evolving serotonin syndrome spectrum: from acute syndrome to smoldering presentations and personalized risk management	5
In silico prediction of drug-induced nephrotoxicity: current progress and pitfalls	5
A critical review of methotrexate clinical interactions: role of transporters	5
Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis	5
Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond	5
CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?	5
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	5
Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?	5
Pharmacokinetics and safety of the combination of KL130008 and methotrexate in rheumatoid arthritis patients: a multicenter, open-label phase Ib trial	5
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy	5
A novel in vivo approach to monitoring Cyp3a induction and inhibition by bioluminescent urinalysis	5
Cannabidiol: metabolism and clinical efficacy in epileptic patients	5
Transporters and drug secretion into human breast milk	5
Drug-drug interactions in patients living with HIV who undergo solid organ transplant	5
The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?	5
Pharmacokinetic drug evaluation of co-packaged sulbactam for injection and durlobactam for injection for the treatment of Acinetobacter baumannii-calcoaceticus	5
Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections	5
Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects	4
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review	4
Assessing DDI risks in drug discovery and development: approaches, challenges, and trends	4
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke	4
A repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in NOG mice by intravenous injection	4
Sex-specific UGT expression and function: prevalence, potential mechanisms and significance	4
Improving on in-silico prediction of oral drug bioavailability	4
Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates	4
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro	4
The clinical implication of inflammation-driven regulation of drug-metabolizing enzymes	4
JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations	4
Sex-gender differences in pharmacokinetics	4

What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities?	4
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	4
Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older	4
Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future	4
Impact of pediatric continuous renal replacement therapy parameters on meropenem, piperacillin, and tazobactam pharmacokinetics: an in vitro model	4
Epigenetics is involved in the pleiotropic effects of statins	4
Inositols in the ovaries: activities and potential therapeutic applications	4
Comparison of ADMET profile between thiosemicarbazide and semicarbazide derivatives regarding anticancer properties	4
The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review	4
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration	4
Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation	4
Suboptimal concentrations of isavuconazole in critically ill patients treated for mold infections: a population pharmacokinetic analysis	4
What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?	4
Where developmental toxicity meets explainable artificial intelligence: state-of-the-art and perspectives	4
Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research	4
A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations	3
Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease	3
The quest to define cancer-specific systems parameters for personalized dosing in oncology	3
Therapeutic drug monitoring of TNFα inhibitors: a spotlight on novel techniques and assays	3
Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment	3
The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions	3
Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting	3
Drug-drug interactions between COVID-19 therapeutics and psychotropic medications	3
Correction	3
Chitosan-functionalized bentonite nanostructure as a promising compound to reduce the toxicity of aflatoxin B1: an in vitro and in	3
Pharmacogenetic guided drug therapy – how to deal with phenoconversion in polypharmacy	3
Deep learning neural network derivation and testing to distinguish acute poisonings	3
Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil	3
Preventable serious drug-disease interactions of reserve antibiotics	3
Safety of medicines during breastfeeding – from case report to modeling: a contribution from the ConcePTION project	3
Mass balance and metabolite profiles in humans of tegoprazan, a novel potassium-competitive acid blocker, using 14 C-radiolabelled techniques	3
Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications	3
Phytoconstituents as therapeutic agents in combating methotrexate-induced hepatotoxicity and nephrotoxicity	3
Drug-induced liver injury associated with the use of newer antiseizure medications in the elderly: an analysis of data from VigiBase	3
Clinical considerations on the use of antiretrovirals and renal impairment	3
Modeling drug-induced liver injury: current status and future prospects	3
Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations	3